Records identified through database\* searching:

n = 6,690

Databases\*:

**CINHAL:** 856, **PubMed:** 1751, **Embase:** 4,083

**Identification**

Records after duplicate removal

(n = 3,825)

● 2,188 records excluded as not related to MERS-CoV

● 91 records excluded as only abstracts were available

**Screening**

Title and abstract screening

(n = 3,825)

Full-text records excluded (n = 282) for the following reasons:

* Duplication (n=6)
* Not related to MERS-CoV (n=35)
* Not study type of interest (n=198)
* Records in languages other than English (n=43):

Chinese (n=16), French (n=3), Japanese (n=1)

Korean (n=11), Polish (n=1), Russian (n=1)

Spanish (n=2), Deutsch (n=2), Greek (n=1)

Turkish (n=2), Nordic (n=2), Persian (n=1)

**Eligibility**

Full-text records assessed for eligibility

(n = 1,546)

Studies included

(n = 1,264)

**Included**

Figure 1: **PRISMA:** *Flowchart of the selection process for the scoping review of the Middle East Respiratory Syndrome Coronavirus studies and results, (1 January 2012 to 24 January 2023)*

|  |  |
| --- | --- |
|  | 100 – 300 records |
|  | 50 – 99 records |
|  | 10 – 49 records |
|  | 1 – 9 records |
|  | 0 records |

**Figure 2:** Map of first-author countries that conducted studies on MERS-CoV, (1 January 2012 to 24 January 2023)

**Figure 5:** *Number of MERS-CoV-related studies included in the scoping review by themes, (1 January 2012 to 24 January 2023)*